KROSKeros Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Keros Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KROSThis | $219M#6 | — | 0.8x#1 | 0.9x#1 | 6775.0%#1 | 146.4%#1 | 27.7%#1 | 33.2%#1 | — | — | -27.3%#2 | — |
| KRRO | $239M#1 | — | 2.3x#4 | 37.4x#3 | 181.5%#3 | -40.3%#2 | -1906.4%#4 | -113.6%#4 | -155.2%#1 | — | -55.7%#3 | — |
| GTBP | $237M#2 | 1.0x#1 | 66.5x#5 | — | — | -115.4%#6 | — | -794.5%#5 | — | — | — | 0.1%#1 |
| CAMP | $236M#3 | — | — | 67.5x#4 | 436.5%#2 | -55.2%#4 | -1502.4%#3 | — | — | — | — | — |
| VNDA | $236M#4 | — | 1.2x#3 | 1.1x#2 | 8.7%#4 | -1066.7%#7 | -70.0%#2 | -110.3%#3 | — | — | — | — |
| CTNM | $226M#5 | — | 0.9x#2 | — | -100.0%#6 | -41.9%#3 | — | -25.0%#2 | — | — | — | — |
| RNAC | $193M#7 | — | — | 483.3x#5 | -99.0%#5 | -68.3%#5 | -35851.3%#5 | — | — | — | -21.4%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice